Table 1.

Responses of tumor cell lines and corresponding xenografts to BAY-8002 and AZD3965

Cell proliferation inhibitionIn vivo (xenograft)
ModelIndicationCompoundIC50 (nmol/L)Efficacy (%)Dose(mg/kg 2QD)T/C
RajiBurkitt lymphomaBAY-8002666100800.59a
AZD396513100500.31a
DaudiBurkitt lymphomaBAY-8002154075800.80
AZD39655675500.60a
WSU-DLCL2Diffuse large cell lymphomaBAY-8002652100800.98
AZD39657100500.68
COLO320DMColorectalBAY-800278280801.16
AZD39651.780801.20
  • NOTE: Efficacy is defined as a percentage of the greatest attainable growth inhibition response. P values for treatment compared with vehicle control based on final tumor weights. Statistical significance was determined by one-way ANOVA followed by multiple comparison versus control group procedure (Holm–Sidak).

  • Abbreviations: T/C, tumor over control final tumor weights; 2QD, twice a day.

  • aP value < 0.01.